TD Cowen Initiates Coverage on Inventiva (NASDAQ:IVA)

Research analysts at TD Cowen initiated coverage on shares of Inventiva (NASDAQ:IVA - Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set a "buy" rating and a $10.00 price target on the stock. TD Cowen's price objective indicates a potential upside of 224.68% from the stock's current price.

Several other brokerages also recently commented on IVA. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price target on shares of Inventiva in a research report on Thursday, January 30th. UBS Group initiated coverage on shares of Inventiva in a research report on Tuesday, November 12th. They set a "neutral" rating and a $3.00 target price on the stock. Finally, Stifel Nicolaus reduced their price target on shares of Inventiva from $20.00 to $17.00 and set a "buy" rating for the company in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.60.

Inventiva Trading Up 5.8 %

Shares of NASDAQ:IVA traded up $0.17 during midday trading on Friday, hitting $3.08. The company's stock had a trading volume of 12,461 shares, compared to its average volume of 9,460. The stock's 50 day simple moving average is $2.34 and its 200 day simple moving average is $2.37. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $4.50.

Remove Ads

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.